PDCD1 and non-small cell lung carcinoma: One study of NSCLC using PD-1 antibody for initial treatment had an ORR and DCR of 21.1% and 63.2%, respectively, and re-immunotherapy with a PD-L1 antibody had an ORR of 2.6% and a DCR of 34.2% (29).